Company intelligence / Profile preview

Histatrol

Hørsholm, Denmark

Ownership: Private
Employees: ~2700
Development stage: Other

Overview

ALK-Abelló is a global pharmaceutical company specializing in the development and commercialization of allergy immunotherapy (AIT) products and diagnostic solutions. The company is best known for its extensive portfolio of allergenic extracts and its line of sublingual immunotherapy (SLIT) tablets, such as ACARIZAX and ODACTRA. ALK also manufactures Histatrol, a standardized histamine phosphate injection used as a positive control in skin testing to evaluate immediate hypersensitivity. Headquartered in Denmark, the company operates a vertically integrated business model covering research, development, and large-scale manufacturing of allergy treatments and diagnostics.

Therapeutic areas: PulmonologyImmunology
Modalities: BiologicSmall moleculeVaccine
Industry: Biotech

Partnerships

Torii PharmaceuticalMerck & Co.

Beyond the preview

Go deeper on Histatrol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histatrol.

Explore the full profile